Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1177-1183

  Jones, Stephen ^a   Holmes, Frankie Ann ^a   O'Shaughnessy, Joyce ^a   Blum, Joanne L ^a   Vukelja, Svetislava J ^a   Mclntyre, Kristi J ^a   Pippen, John E ^a   Bordelon, James H ^a   Kirby, Robert L ^a   Sandbach, John ^a   Hyman, William J ^a   Richards, Donald A ^a   Mennel, Robert G ^a   Boehm, Kristi A ^a   Meyer, Wally G ^a   Asmar, Lina ^a   Mackey, Daniel ^a   Riedel, Stefan ^a   Muss, Hyman ^a   Savin, Michael A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TAXOIDS;

EID: 62449193617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.4028     Document Type: Article

References (27)

1. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
2. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699-3704, 2007
3. Jones SE: In reply. J Clin Oncol 25:4327, 2007
4. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. JASA 53:457-481,1958
5. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node positive breast cancer. N Engl J Med 352:2301-2313, 2005
6. Roche H, Fumoleau P, Spielmann M, et al: Sequential adjucant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 24:24:5664-5671, 2006
7. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential pacli- taxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
8. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431- 1439, 2003
9. Hudis C, Citron M, Berry D, et al: Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. Presented at the 2005 San Antonio Breast Cancer Symposium December 8-11, San Antonio, TX (abstract 41)
10. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
11. American Society of Clinical Oncology 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. http://www.asco.org/ASCO/ Quality+Care+%26+Guidelines/ Practice+Guidelines/ Clinical+ Practice+Guidelines/Supportive+Care+and+ Quality+of +Life/American + Society+of+Clinical + Oncology+2006+Update+of+Recommendations+for +the+Use+of+White+Blood+Cell+Growth+Factors% 3A+An+Evidence- Based+Clinical+Practice+Guideline
12. Patt DA, Duan Z, Fang S, et al: Acute myeloid leukemia after adjuvant breast cancer therapy in older women: Understanding risk. J Clin Oncol 25: 3871-3876, 2007
13. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293: 1073-1081, 2005
14. Patt DA, Duan Z, Hortobagyi G: Acute myeloid leukemia in older women after adjuvant breast cancer therapy. J Clin Oncol 24:560, 2006 (abstr)
15. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
16. brahim NK, Buzdar AU, Asmar L, et al: Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up. Ann Oncol 11:1597- 1601, 2000
17. Fumoleau P, Roché H, Kerbrat P, et al: Long- term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17:85-92, 2006
18. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007
19. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
20. Hayes DF, Thor AD, Dressier LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
21. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
22. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
23. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
24. nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastu- zumab (AC→TH) with docetaxel, carboplatin, and tras- tuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at the 2006 San Antonio Breast Cancer Symposium, San Antonio, TX, December 14- 17, 2006 (LBA52)
25. Slamon DJ, Mackey J, Robert N, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. Presented at the 2007 San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, TX (abstr 13)
26. O'Malley FP, Chia S, Tu D, et al: Topoisomer- ase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). Presented at the 2006 San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 38)
27. Pritchard Kl, Messersmith H, Elavathil L, et al: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008